2009RePEc: Research Papers in EconomicsOpen access

Biosafety decisions and perceived commercial risks: The role of GM-free private standards

Guillaume Gruère, Debdatta Sengupta

Open full text 13 citations

Abstract

We herein investigate the observed discrepancy between real and perceived commercial risks associated with the use of genetically modified (GM) products in developing countries. We focus particularly on the effects of GM-free private standards set up by food companies in Europe and other countries on biotechnology and biosafety policy decisions in food-exporting developing countries. Based on field visits made to South Africa, Namibia, and Kenya in June 2007, and secondary information from the press and various publications, we find 31 cases of interactions between private GM-free standards and biosafety policy decisions in 21 countries. Although we cannot infer the direct involvement of supermarkets and food companies in biosafety policy processes in developing countries, we find that by setting up GM-free standards, these actors are indirectly influential via their local traders, who face the possibility of exclusion if they do not comply with the standards. Organic producers? and anti-GM organizations also play a role in spreading perceptions of commercial risks that are not always justified. By comparing cases, we differentiate three types of relevant commercial risks: real risks, potential risks, and unproven risks. We then identify two critical, yet misleading, presumptions perpetuated by the various interest groups to spread the fear of potential or unproven risks: the infeasibility of non-GM product segregation and the lack of alternative buyers. We also find that information asymmetries and risk-averse behaviors related to perceived market power can help insert unfounded export concerns into biosafety or biotechnology policy decisions. The results of our analysis are used to suggest a simple framework to separate real commercial risks from others, based on five critical questions designed to aid decision makers when they face pressures to reject GM crop testing, application, consumption or use for fear of alleged export losses.

Open-access reader

About this research paper

What this paper is about

We herein investigate the observed discrepancy between real and perceived commercial risks associated with the use of genetically modified (GM) products in developing countries. We focus particularly on the effects of GM-free private standards set up by food companies in Europe and other countries on biotechnology and biosafety policy decisions in food-exporting developing countries. Based on field visits made to South Africa, Namibia, and Kenya in June 2007, and secondary information from the press and various publications, we find 31 cases of interactions between private GM-free standards and biosafety policy decisions in 21 countries. Although we cannot infer the direct involvement of supermarkets and food companies in biosafety policy processes in developing countries, we find that by setting up GM-free standards, these actors are indirectly influential via their local traders, who face the possibility of exclusion if they do not comply with the standards. Organic producers? and anti-GM organizations also play a role in spreading perceptions of commercial risks that are not always justified. By comparing cases, we differentiate three types of relevant commercial risks: real risks, potential risks, and unproven risks. We then identify two critical, yet misleading, presumptions perpetuated by the various interest groups to spread the fear of potential or unproven risks: the infeasibility of non-GM product segregation and the lack of alternative buyers. We also find that information asymmetries and risk-averse behaviors related to perceived market power can help insert unfounded export concerns into biosafety or biotechnology policy decisions. The results of our analysis are used to suggest a simple framework to separate real commercial risks from others, based on five critical questions designed to aid decision makers when they face pressures to reject GM crop testing, application, consumption or use for fear of alleged export losses.

Why it matters

OpenAlex reports 13 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

We herein investigate the observed discrepancy between real and perceived commercial risks associated with the use of genetically modified (GM) products in developing countries. We focus particularly on the effects of GM-free private standards set up by food companies in Europe and other countries on biotechnology and biosafety policy decisions in food-exporting developing countries. Based on field visits made to South Africa, Namibia, and Kenya in June 2007, and secondary information from the press and various publications, we find 31 cases of interactions between private GM-free standards and biosafety policy decisions in 21 countries. Although we cannot infer the direct involvement of supermarkets and food companies in biosafety policy processes in developing countries, we find that by setting up GM-free standards, these actors are indirectly influential via their local traders, who face the possibility of exclusion if they do not comply with the standards. Organic producers? and anti-GM organizations also play a role in spreading perceptions of commercial risks that are not always justified. By comparing cases, we differentiate three types of relevant commercial risks: real risks, potential risks, and unproven risks. We then identify two critical, yet misleading, presumptions perpetuated by the various interest groups to spread the fear of potential or unproven risks: the infeasibility of non-GM product segregation and the lack of alternative buyers. We also find that information asymmetries and risk-averse behaviors related to perceived market power can help insert unfounded export concerns into biosafety or biotechnology policy decisions. The results of our analysis are used to suggest a simple framework to separate real commercial risks from others, based on five critical questions designed to aid decision makers when they face pressures to reject GM crop testing, application, consumption or use for fear of alleged export losses.

Key concepts: Biosafety, Business, Product (mathematics), Public economics, Economics, Biotechnology, Geometry, Biology

Related papers

Back to paper searchBrowse research topicsOriginal source
Biosafety decisions and perceived commercial risks: The role of GM-free private standards — Research Paper | ScholarLens